About REPROCELL
REPROCELL provides a unique combination of products and services to power your translational research. With scientists and laboratories on three continents, we have the scientific and clinical expertise to better translate your discoveries into therapies.
REPROCELL's portfolio includes an extensive product catalog to support stem cell research and 3D bioengineered tissues, a commercial biorepository of ethically-sourced human tissues, extensive clinical networks across the US and Europe that enable our contract research services in human ex vivo living tissues, and our capability to supply induced pluripotent stem cells (iPSCs) for both research and clinical applications.
REPROCELL is also developing novel regenerative medicine therapies to treat neurodegenerative disease, based on its expertise in pluripotent stem cells and mesenchymal stem cells, and is currently conducting clinical trials in Japan for the treatment of spinocerebellar ataxia. Its diagnostic services and clinical research services are offered across labs in Japan, the US, UK, and India. Reprocell's expertise in patient recruitment, the logistics, and ethics of accessing human biospecimens and diagnostics is driving the development of new technologies to support biomarker research and precision medicine. Combined with our clinical laboratory facilities, these resources and know-how have positioned REPROCELL as a fully integrated partner for the life sciences industry, with clients across the globe.
Few companies can claim to have such broad business activities and capabilities, making REPROCELL a unique partner for providing you with the services and materials you need to navigate the complex world of drug discovery and regenerative medicine.
Our Scientists
We proudly employ over 100 scientists across the USA, UK, and Japan. Every member of our team is recruited for their expertise and interest in stem cells and human tissue research. You can find out a bit more about some of our researchers and their publications below.
Ejaz Ansari, Laboratory Manager and Study Director
Ejaz Ansari is one of REPROCELL’s resident experts in human fresh tissue research. As a leading authority in Organ bath and Ussing studies, Ejaz is Laboratory Manager at our Center for Predictive Drug Discovery.
Bob Annand, Senior Technical Product Manager
Bob has a PhD in biochemistry and over a decade of experience in drug development. He helped to establish and market several of our stem cell products - including the StemRNA 3rd Gen Reprogramming Kit.
Graeme Macluskie, Precision Medicine Director
Since 2011, Graeme has been designing and delivering preclinical research projects globally. With more than two decades of experience in the industry, he leads an R&D team responsible for tissue-based assays.
Our Values
- Quality: It is at the core of all we do. Investments in people and infrastructure drive quality thinking, quality products and services, and quality customer and patient experiences.
- Innovation: Technical advancement requires that we remain flexible and agile. We are forward-thinking and embody the process of continuous improvement. We are dedicated to cultivating and commercializing cutting-edge research and advanced medical technologies to improve human health.
- Trust: As skilled experts, we are trusted partners in our customer’s success. We seek to build and maintain their trust through honest effort, communication, and transparency.
- Value: We add value by providing tools and services that de-risk, enable and accelerate customer research workflows and medical healthcare applications
- Customer focus: We help solve critical challenges and provide customized results by listening, designing, and implementing solutions to address the unique needs of our clients
The History of REPROCELL
Established in 2003 by preeminent Japanese university researchers, REPROCELL quickly became the leading stem cell research company in Japan. Soon thereafter, REPROCELL products were employed by Professor Shinya Yamanaka during his pioneering research on iPSC technologies at Kyoto University. We were the first company to offer iPSC-derived human cardiomyocytes, hepatocytes, and neuronal cells for research applications and were listed on the Japan JASDAQ / Growth stock market in 2013.
In recent years, REPROCELL has expanded through a series of acquisitions. This expansion has created a workflow - including human tissue acquisition (BioServe®), RNA reprogramming (Stemgent®), 3D technologies (Reinnervate®), and drug discovery (Biopta®) - in addition to our core capabilities. These acquisitions have been consolidated to regional offices, and the names converted to daughter brands. In the stem cell and drug discovery “market- space”, no other company has such a broad combination of expertise that can be applied to drug discovery and regenerative medicine. To find out more about REPROCELL's capabilities, download our Corporate Capabilities Guide (PDF).
Timeline
.jpg?width=900&name=REPROCELL-04.06.18_0460%20(1).jpg)
The Future of REPROCELL
Over the last decade, REPROCELL has evolved its global infrastructure, corporate organization, and strategy. By leveraging our knowledge base of stem cell technologies, REPROCELL has planned a future that directly involves the pursuit of regenerative medicine market opportunities. This evolution has compelled us to restructure, modify, and define our future vision. If you are interested in finding out more, the REPROCELL Corporate Profile Guide (PDF) concisely explains our current organization and provides a guideline for corporate development and operations.
